Merus (NASDAQ:MRUS) Given Outperform Rating at William Blair

Merus (NASDAQ:MRUS)‘s stock had its “outperform” rating reaffirmed by equities researchers at William Blair in a report issued on Monday, RTT News reports.

MRUS has been the topic of several other research reports. Truist Financial assumed coverage on shares of Merus in a report on Thursday, March 28th. They issued a “buy” rating and a $69.00 price target on the stock. BMO Capital Markets upped their target price on shares of Merus from $49.00 to $58.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price target on shares of Merus in a research report on Thursday, April 11th. StockNews.com cut shares of Merus from a “hold” rating to a “sell” rating in a research note on Monday, March 4th. Finally, HC Wainwright raised their target price on shares of Merus from $48.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. One research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Merus presently has an average rating of “Moderate Buy” and a consensus price target of $56.33.

Merus Price Performance

NASDAQ:MRUS opened at $40.82 on Monday. The stock has a market cap of $2.40 billion, a P/E ratio of -13.47 and a beta of 1.10. Merus has a one year low of $18.21 and a one year high of $52.03. The company has a fifty day moving average price of $45.05 and a 200 day moving average price of $33.39.

Merus (NASDAQ:MRUS) last released its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.38). The company had revenue of $8.94 million for the quarter, compared to analyst estimates of $10.43 million. Merus had a negative net margin of 352.56% and a negative return on equity of 50.61%. As a group, equities research analysts anticipate that Merus will post -3.29 EPS for the current year.

Institutional Investors Weigh In On Merus

A number of hedge funds and other institutional investors have recently modified their holdings of MRUS. BluePath Capital Management LLC acquired a new position in Merus in the third quarter valued at about $33,000. Quadrant Capital Group LLC grew its position in Merus by 37.7% in the fourth quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 343 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Merus by 142.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 867 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Merus by 64.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 828 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new position in Merus in the first quarter valued at about $72,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.